Document Detail

Ranolazine in patients with coronary artery disease.
MedLine Citation:
PMID:  17714067     Owner:  NLM     Status:  MEDLINE    
Traditional anti-anginal agents such as beta-blockers and nitrates improve symptoms of cardiac ischemia by affecting either blood pressure or heart rates. Despite aggressive therapy, many patients suffer persistent angina, and optimal therapy is limited by intolerance to traditional agents. Ranolazine, a novel anti-anginal agent that is approved for use in the US, is felt to improve ischemic symptoms by reducing myocardial cellular sodium and calcium overload via inhibition of the late sodium current (I(Na)) of the cardiac action potential. Several Phase-III trials in patients with chronic angina have demonstrated that ranolazine improves exercise tolerance and reduces ischemic symptoms as compared with placebo. In the largest evaluation of ranolazine, the MERLIN-TIMI 36 trial (Metabolic Efficiency with Ranolazine for Less Ischemia in non ST elevation acute coronary syndrome), ranolazine did not reduce the risk of death or recurrent myocardial infarction in patients with non-ST-elevation acute coronary syndromes, but it did improve ischemic symptoms over the subsequent year of therapy. Thus, ranolazine offers clinicians a new therapy in the long-term treatment of patients with chronic angina.
Benjamin M Scirica
Related Documents :
21399557 - Accessory atrioventricular myocardial pathways in mouse heart development: substrate fo...
11825727 - Plasma levels and vascular effects of endothelin and big endothelin in patients with st...
6456087 - The high-risk angina patient. identification by clinical features, hospital course, ele...
8026037 - Vasoreactivity of the culprit lesion in unstable angina.
22988827 - Vascular inflammation and aortic stiffness relate to early left ventricular diastolic d...
8789177 - Salutary effects of myocardial ischemia in coronary artery disease.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  8     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2007 Sep 
Date Detail:
Created Date:  2007-08-23     Completed Date:  2007-09-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2149-57     Citation Subset:  IM    
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetanilides / therapeutic use*
Angina Pectoris / drug therapy,  mortality,  physiopathology
Coronary Artery Disease / drug therapy*,  mortality,  physiopathology
Piperazines / therapeutic use*
Reg. No./Substance:
0/Acetanilides; 0/Piperazines; 110445-25-5/ranolazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibito...
Next Document:  Simvastatin: present and future perspectives.